LONG-TERM SURVIVAL OF SOLID ORGAN ALLOGRAFTS BY BRIEF ANTI-LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 MONOCLONAL ANTIBODY MONOTHERAPY
1996; Wolters Kluwer; Volume: 62; Issue: 5 Linguagem: Inglês
10.1097/00007890-199609150-00001
ISSN1534-6080
AutoresEric K. Nakakura, R. Shorthouse, Biru Zheng, Susan McCabe, Paula Jardieu, Randall E. Morris,
Tópico(s)Immune Cell Function and Interaction
ResumoStrategies targeting lymphocyte function-associated antigen-1(LFA-1, CD11a/CD18) and intercellular adhesion molecule-1 (ICAM-1) have previously been shown to produce long-term survival of solid organ allografts in animals only when both CD11a and ICAM-1 are targeted for a brief (6-7 days) time or when extended (14 weeks) treatment with anti-CD11a monoclonal antibody(mAb) is administered. We show that recipient pretreatment followed by a brief(13 days) treatment course with high-dose anti-CD11a mAb alone produces long-term survival of cardiac allografts in the rigorous, nonprimarily vascularized heart allograft model in mice. This treatment regimen induces specific unresponsiveness in our model. In recipients bearing long-term beating cardiac grafts after treatment with anti-CD11a mAb, there still exists a high frequency of potentially antigen-reactive T cells in isolated peripheral blood lymphocyte fractions. Therefore, clonal deletion does not appear to explain the induction of specific unresponsiveness by treatment with anti-CD11a mAb in this model. These findings support the further investigation of the use of high-dose anti-LFA-1 mAb monotherapy in the pre- and early postoperative period to promote solid organ allograft survival.
Referência(s)